From the Editor
Paring the Fat in Clinical Trials
New research from the Tuft's Center for the Study of Drug Development provides answers to some basic strategic questions: what is contributing to the run-up in costs in trial protocols, and where and how can savings be made?
...Read more
eMarketing
What is "Big Data" and How Can We Use It?
Why, with all the data available, are pharma companies so bad at getting true marketing insights to drive their business? Bill Drummy asks how marketers can realize the promise of "Big Data" ...Read More
Global
Open Access to Sweep Europe?
After almost simultaneous announcements by the UK government and the European Commission, Europe looks set for a radical shake-up of academic publishing and access to scientific research ...Read More
UK
Naughty Localities Need to Obey NICE, or Else!
Like US state governors vowing to block Medicaid expansion in their home states, local primary care trusts (PCTs) in the UK don’t always follow national guidelines on drug access due to budgetary concerns. But that may change in 2013; according to comments made by Minister David Willetts last month, NHS could face monetary penalties for not making newly approved drugs available to patients fast enough ...Read more |
